###### Strengths and limitations of this study

-   In a cohort of 9525 patients undergoing total hip arthroplasties (THAs), we found that 5% of the patients were chronic opioid users after their surgery. Of these, 61% were persistent chronic users (ie, had been chronic opioid users prior to surgery and continued after surgery), and 39% became chronic users after surgery.

-   This study also identified indicators of chronic opioid use that can be used by clinicians for risk stratification prior to surgery, and to target patient groups for suitable pain management interventions presurgery and postsurgery. Specifically, back pain, diabetes and preoperative use of hypnotics were strong risk factors for the persistent and new development of chronic opioid use. Additional risk factors for persistent use included younger age and greater use of opioids prior to surgery, while for new chronic use these included being a woman, depression, migraine, gastric acid disease and antineuropathic pain medications.

-   The limitations of this study include a conservative definition of chronic opioid as someone who was prescribed opioids for 90 consecutive days or 120 non-consecutive days, and inability to determine the specific reasons why analgesic medications were prescribed to patients.

-   The strengths of this study include a large and fully captured patient cohort (ie, no missing data and attrition only related to death), a comprehensive assessment of patient comorbidities using three comorbidity measures, and the use of pharmacy data to determine opioid use instead of patient-reported use which can suffer from response bias.

Background {#s1}
==========

Total hip arthroplasty (THA) is the recommended treatment for patients with hip osteoarthritis that have failed both pharmacological and non-pharmacological treatment for the severe pain, and limited function caused by their condition.[@R1] THA is the fourth most common surgical procedure in the USA, with 468 000 performed in 2012[@R2]; it is one of the top 20 most common surgical procedures in Australia, with 26 000 performed in 2013.[@R3] THA is considered a clinically effective, successful operation with reported cost-effectiveness.[@R1] However, while joint-related pain is expected to be resolved after surgical rehabilitation, there is a high prevalence of patients who report persistent chronic pain and some patients who report chronic pain development subsequent to the procedure.[@R4]

Chronic and persistent pain post-THA occurs in 7--23% of patients.[@R4] [@R5] One study reported moderate-to-severe hip pain after primary THA in 8% of patients.[@R6] Other studies suggested that 3--25% of patients take opioid medications for almost 5 years after their surgery.[@R6] [@R7] There are several reasons that suggest the use of opioids in patients with THA is high, and abuse of these medications could affect these patients. First, it is well established that the use of opioids has increased worldwide for all non-cancer chronic pain management.[@R8] In the treatment of musculoskeletal pain, opioids use increased by 50% between 2006 and 2010,[@R12] and surgeons are reportedly some of the highest prescribers of these medications.[@R13] Second, as opioids are recommended for the treatment of osteoarthritis[@R1] and surgical recovery,[@R14] patients undergoing THA are likely to be exposed to opioids for long periods of time, increasing their chance of developing tolerance, hyperalgesia,[@R15] and other dangerous and potentially costly opioid-related side effects.[@R16] Third, the comorbidity burden of patients undergoing THA has increased in the past two decades,[@R17] suggesting that patients can, and are likely to, be suffering from other types of pain and taking opioids for these other conditions, which also affect their surgical outcomes.[@R20] Finally, in addition to the high exposure to these medications, there is the potential of adverse events associated with opioid use in surgical recovery.[@R14] The higher medical complexity of the patients undergoing THA creates potential interactions between these opioid medications and the specific surgical outcomes of the procedure. Currently it is not well understood how opioids are used in this patient population and who is at risk of harm.

Understanding who is at risk of persistent chronic opioid use and developing new chronic use in this patient population can be useful to the surgeons, the patients themselves and the general healthcare system of which they are a part. Our study was conducted to identify patients at a high risk of chronic opioid use who may benefit from targeted interventions for better pain management strategies and opioid use education. Specifically, the purpose of this study was to (1) determine the prevalence of chronic opioid use before and after THA surgery, and (2) determine the characteristics associated with persistent chronic opioid use or becoming a new chronic user after surgery.

Methods {#s2}
=======

Study design, setting and study sample {#s2a}
--------------------------------------

A retrospective cohort study was conducted. Patients who underwent a THA procedure between 1/01/2001 and 12/31/2012 were included in the study. The study cohort comprised of patients who received care subsidised by the Australian Government Department of Veterans\' Affairs (DVA). The DVA administrative claims database, which includes detailed information on all inpatient hospitalisations, prescription medications, medical procedures and allied health services provided to veterans, was used for the study. The DVA\'s client file, which contains information on gender, date of birth, date of death and family status for a treatment population of 242 000 veterans and spouses in September 2011, was also used. In the prescription data set, medications are coded according to the WHO anatomic, therapeutic and chemical classification (ATC),[@R21] and the Australian Pharmaceutical Benefits Schedule (PBS) item codes.[@R22] In the inpatient hospitalisation data set, encounters are coded using the International Classification of Diseases, 10th Revision, Australian Modification (ICD-10-AM) codes.[@R23]

Patients older than 18 years of age were selected for the study if they underwent elective unilateral THA (identified using ICD-10-AM procedure code 4 931 800), did not have other hip or knee arthroplasties within 1 year of the index THA, and did not have history of cancer (ICD-10-AM C00.x--C26.x, C30.x--C34.x, C37.x--C41.x, C43.x, C45.x--C58.x, C60.x--C76.x, C81.x--C85.x, C88.x,C90.x--C97.x, C77.x--C80.x, C81.x--C85.x, C88.x, C96.x, C90.0, C90.2 and antineoplastic and immunomodulating agents medication history ATC codes L01\*). The cohort was initially comprised of 10018 THAs belonging to 9373 patients. Of these, 493 THAs were not included in the final sample as they either experienced a revision (N=202) or died (N=290) within a year of surgery or did not have complete 1-year follow-up (N=1). Patients with revisions or who died within 1 year were excluded to reduce the effect these events could have on the amount of opioids a patient would take; thus, an accurate description of chronic opioid use could be determined. The final cohort comprised 9525 THAs given to 8925 patients (8325 patients had one THA and 600 had two surgeries more than 1 year apart).

Outcomes of interest {#s2b}
--------------------

Chronic opioid use after surgery was the main outcome of interest. Chronic opioid use was defined as having any number of opioid prescriptions or dosing for at least 90 days continuously, or opioid prescriptions for 120 non-consecutive days.[@R24] The number of days was obtained from the number of units supplied. No gap days between one prescription supply and another were allowed when determining consecutive prescription of opioids. New chronic users were those who did not have chronic use prior to their THA. Persistent chronic opioid users were those with chronic opioid use before and after surgery.

Opioids (ATC code=N02A\*, inclusive of opioid-like medications such as Tramadol) 365 days pre-THA (admission date) and post-THA (discharge date) were extracted from the DVA prescription database, and the number of dispensed prescriptions and the days of expected utilisation were calculated. Dosages were converted to oral morphine equivalents (OMEs),[@R25] and the daily OMEs were summed across the days within the pre-THA and post-THA periods to estimate the total OME for these time periods. When determining whether patients were chronic opioid users post-THA, the immediate 90-day period after THA was excluded as the use of opioids in this period is related to surgical recovery and rehabilitation. Therefore, each patient had 275 potential days of medication utilisation post-THA. To obtain a similar exposure period preoperatively, we excluded the 90-day period between 365 and 275 days prior surgery. Patients were assigned to the opioid use categories of 'chronic', 'some' and 'none' opioid use for the periods of pre-THA and post-THA. After classifying chronic users, the remaining opioid users were classified as 'some' opioid use if they did not fit the chronic criteria, and those without any opioid dispensing were assigned to the 'none' category.

Risk factors {#s2c}
------------

Age, sex, surgical indication, bilaterality, opioid-related comorbidities, other medical comorbidities and other analgesic medication were evaluated as risk factors of persistent or new chronic opioid use after surgery. Comorbidities were identified using a combination of the RxRisk-V, Elixhauser and Charlson measures.[@R26] [@R27] Using these three comorbidity measures provided a comprehensive ascertainment of conditions because it used both medication dispensing history and hospital encounters of the patients in the year prior to their surgery. The opioid-related comorbidities investigated included depression, back pain, anxiety, psychoses, alcohol abuse, bipolar disorder and drug abuse. The 49 medical comorbidities investigated, which included cardiovascular and blood, endocrine, gastrointestinal, musculoskeletal, neurological, nutritional, renal, respiratory, and other body systems, can be seen in [table 1](#BMJOPEN2015010664TB1){ref-type="table"}. Additional analgesic medication evaluated included non-steroids anti-inflammatories (ATC code=M01A\*), muscle relaxants (ATC code=M03\*), antineuropathic pain medications (ATC codes=N06AA09, N06AX21, N03AX12, N03AX16),[@R28] hypnotics (ATC code=N05C\*, inclusive of sedatives) and corticosteroids (ATC codes=H02AA\*, H02AB\*). Since the comorbidities of pain treated with opioids, pain treated with anti-inflammatory medications and steroid-responsive disorders were identified using only the RxRisk-V medication comorbidity measure we did not include them in our final analyses, as these are likely to be highly correlated to the other analgesic medication evaluated. Days of opioid use (per quartile of days) and average daily use were investigated as risk factors for persistent chronic opioid use.

###### 

Descriptive characteristics of the total hip arthroplasty study cohort

  Characteristic                                      All           None          Some          Chronic
  --------------------------------------------------- ------------- ------------- ------------- -------------
  Total, n (%)                                        9525          5138 (53.9)   3794 (39.8)   593 (6.2)
  Age at surgery, median (5th--95th centile), years   80 (76--84)   81 (63--88)   80 (61--89)   81 (59--89)
  Sex, n (%)                                                                                    
   Women                                              4891 (51.3)   2558 (49.8)   1977 (52.1)   356 (60.0)
   Men                                                4634 (48.7)   2580 (50.2)   1817 (47.9)   237 (40.0)
  Bilateral (more than 365 days), n (%)               1200 (12.6)   669 (13.0)    473 (12.5)    58 (9.8)
  Year of operation, n (%)                                                                      
   2001--2002                                         1738 (18.2)   1001 (19.5)   694 (18.3)    43 (7.3)
   2003--2004                                         1840 (19.3)   980 (19.1)    786 (20.7)    74 (12.5)
   2005--2006                                         1654 (17.4)   925 (18.0)    651 (17.2)    78 (13.2)
   2007--2008                                         1590 (16.7)   853 (16.6)    612 (16.1)    125 (21.1)
   2009--2010                                         1454 (15.3)   750 (14.6)    572 (15.1)    132 (22.3)
   2011--2012                                         1249 (13.1)   629 (12.2)    479 (12.6)    141 (23.8)
  Surgical indication, n (%)                                                                    
   ICD-10-AM M161: other primary osteoarthritis       7826 (82.2)   4241 (82.5)   3092 (81.5)   493 (83.1)
   ICD-10-AM M169: osteoarthritis unspecified         882 (9.3)     513 (10.0)    342 (9.0)     27 (4.6)
   Other                                              817 (8.6)     384 (7.5)     360 (9.5)     73 (12.3)
  Opioid-related comorbidities                                                                  
   Depression, n (%)                                  1695 (17.8)   755 (14.7)    764 (20.1)    176 (29.7)
   Back pain, n (%)                                   1367 (14.4)   466 (9.1)     694 (18.3)    207 (34.9)
   Anxiety, n (%)                                     1167 (12.3)   445 (8.7)     569 (15.0)    153 (25.8)
   Psychoses, n (%)                                   191 (2.0)     96 (1.9)      74 (2.0)      21 (3.5)
   Alcohol abuse, n (%)                               88 (0.9)      36 (0.7)      45 (1.2)      7 (1.2)
   Bipolar disorder, n (%)                            26 (0.3)      14 (0.3)      11 (0.3)      1 (0.2)
   Drug abuse, n (%)                                  11 (0.1)      4 (0.1)       3 (0.1)       4 (0.7)
  Cardiovascular/blood comorbidities                                                            
   Hypertension, n (%)                                5384 (56.5)   2789 (54.3)   2215 (58.4)   380 (64.1)
   Anticoagulation agents/coagulopathy, n (%)         5071 (53.2)   2676 (52.1)   2077 (54.7)   318 (53.6)
   Hyperlipidaemia, n (%)                             3621 (38.0)   1819 (35.4)   1534 (40.4)   268 (45.2)
   IHD hypertension, n (%)                            3341 (35.1)   1722 (33.5)   1392 (36.7)   227 (38.3)
   Antiplatelet agents, n (%)                         3213 (33.7)   1594 (31.0)   1377 (36.3)   242 (40.8)
   Arrhythmias, n (%)                                 1837 (19.3)   937 (18.2)    774 (20.4)    126 (21.2)
   Congestive heart failure, n (%)                    1277 (13.4)   556 (10.8)    585 (15.4)    136 (22.9)
   Angina, n (%)                                      1112 (11.7)   484 (9.4)     530 (14.0)    98 (16.5)
   Myocardial infarction, n (%)                       241 (2.5)     112 (2.2)     112 (3.0)     17 (2.9)
   Peripheral vascular disease, n (%)                 225 (2.4)     105 (2.0)     100 (2.6)     20 (3.4)
   Valvular disease, n (%)                            225 (2.4)     118 (2.3)     96 (2.5)      11 (1.9)
   Cerebrovascular disorders, n (%)                   201 (2.1)     90 (1.8)      95 (2.5)      16 (2.7)
   Pulmonary circulation disorders, n (%)             109 (1.1)     54 (1.1)      42 (1.1)      13 (2.2)
  Endocrine comorbidities                                                                       
   Diabetes uncomplicated, n (%)                      1007 (10.6)   474 (9.2)     440 (11.6)    93 (15.7)
   Hypothyroidism, n (%)                              674 (7.1)     348 (6.8)     260 (6.9)     66 (11.1)
   Diabetes with complications, n (%)                 624 (6.6)     284 (5.5)     281 (7.4)     59 (9.9)
   Pancreatic insufficiency, n (%)                    15 (0.2)      4 (0.1)       10 (0.3)      1 (0.2)
  Gastrointestinal comorbidities                                                                
   Gastric acid disorder, n (%)                       4267 (44.8)   1981 (38.6)   1904 (50.2)   382 (64.4)
   Liver disease (severe) or failure, n (%)           361 (3.8)     121 (2.4)     173 (4.6)     67 (11.3)
   Peptic ulcer disease, n (%)                        95 (1.0)      47 (0.9)      40 (1.1)      8 (1.3)
   Inflammatory bowel syndrome, n (%)                 80 (0.8)      40 (0.8)      37 (1.0)      3 (0.5)
   Liver disease (mild), n (%)                        25 (0.3)      9 (0.2)       13 (0.3)      3 (0.5)
   Hepatitis C, n (%)                                 0 (0.0)       0 (0.0)       0 (0.0)       0 (0.0)
  Musculoskeletal/pain-related comorbidities                                                    
   Osteoporosis/Paget\'s, n (%)                       1189 (12.5)   564 (11.0)    496 (13.1)    129 (21.8)
   Gout, n (%)                                        950 (10.0)    471 (9.2)     407 (10.7)    72 (12.1)
   RA/collage vascular disorders, n (%)               108 (1.1)     32 (0.6)      62 (1.6)      14 (2.4)
   Migraine, n (%)                                    28 (0.3)      9 (0.2)       11 (0.3)      8 (1.3)
  Neurological comorbidities                                                                    
   Dementia, n (%)                                    191 (2.0)     97 (1.9)      65 (1.7)      29 (4.9)
   Epilepsy                                           421 (4.4)     143 (2.8)     210 (5.5)     68 (11.5)
   Parkinson\'s disease, n (%)                        152 (1.6)     62 (1.2)      70 (1.8)      20 (3.4)
   Other neurological disorders, n (%)                119 (1.2)     60 (1.2)      47 (1.2)      12 (2.0)
   Paralysis (or paraplegia/hemiplegia), n (%)        63 (0.7)      26 (0.5)      32 (0.8)      5 (0.8)
  Nutritional/obesity comorbidities                                                             
   Deficiency anaemia, n (%)                          152 (1.6)     65 (1.3)      72 (1.9)      15 (2.5)
   Obesity, n (%)                                     146 (1.5)     57 (1.1)      77 (2.0)      12 (2.0)
   Weight loss, n (%)                                 87 (0.9)      31 (0.6)      49 (1.3)      7 (1.2)
   Blood loss anaemia, n (%)                          60 (0.6)      24 (0.5)      29 (0.8)      7 (1.2)
   Malnutrition, n (%)                                16 (0.2)      9 (0.2)       5 (0.1)       2 (0.3)
   Hyperkalaemia, n (%)                               3 (0.0)       3 (0.1)       0 (0.0)       0 (0.0)
  Renal/urological                                                                              
   Renal disease/failure, n (%)                       410 (4.3)     168 (3.3)     196 (5.2)     46 (7.8)
   Benign prostatic hypertrophy, n (%)                352 (3.7)     189 (3.7)     137 (3.6)     26 (4.4)
  Respiratory comorbidities                                                                     
   Reactive airway disease, n (%)                     1978 (20.8)   931 (18.1)    888 (23.4)    159 (26.8)
   Chronic pulmonary disease, n (%)                   504 (5.3)     230 (4.5)     228 (6.0)     46 (7.8)
   Tuberculosis, n (%)                                0 (0.0)       0 (0.0)       0 (0.0)       0 (0.0)
  Miscellaneous comorbidities                                                                   
   Allergies, n (%)                                   1327 (13.9)   592 (11.5)    618 (16.3)    117 (19.7)
   Glaucoma, n (%)                                    897 (9.4)     494 (9.6)     356 (9.4)     47 (7.9)
   Smoking, n (%)                                     90 (0.9)      32 (0.6)      53 (1.4)      5 (0.8)
   Psoriasis, n (%)                                   46 (0.5)      19 (0.4)      24 (0.6)      3 (0.5)
   Transplant, n (%)                                  2 (0.0)       1 (0.0)       1 (0.0)       0 (0.0)
   HIV, n (%)                                         0 (0.0)       0 (0.0)       0 (0.0)       0 (0.0)
  *Other analgesic medication use*                                                              
  Pre-THA                                                                                       
   NSAIDs, n (%)                                      6093 (64.0)   3007 (58.5)   2722 (71.7)   364 (61.4)
   Hypnotics and sedatives, n (%)                     1904 (20.0)   693 (13.5)    1012 (26.7)   199 (33.6)
   Corticosteroids, n (%)                             1275 (13.4)   474 (9.2)     672 (17.7)    129 (21.8)
   Antineuropathic pain, n (%)                        657 (6.9)     205 (4.0)     333 (8.8)     119 (20.1)
   Muscle relaxants, n (%)                            27 (0.3)      7 (0.1)       17 (0.4)      3 (0.5)
  Post-THA                                                                                      
   NSAIDs, n (%)                                      4288 (45.0)   2033 (39.6)   1969 (51.9)   286 (48.2)
   Hypnotics and sedatives, n (%)                     1950 (20.5)   762 (14.8)    982 (25.9)    206 (34.7)
   Corticosteroids, n (%)                             1242 (13.0)   497 (9.7)     623 (16.4)    122 (20.6)
   Antineuropathic pain, n (%)                        678 (7.1)     233 (4.5)     326 (8.6)     119 (20.1)
   Muscle relaxants, n (%)                            24 (0.3)      5 (0.1)       15 (0.4)      4 (0.7)

Overall and by preoperative opioid utilisation status, 2001--2012. ICD-10-AM, International Classification of Diseases, 10th Revision, Australian Modification; NSAID, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; THA, total hip arthroplasty.

Statistical analyses {#s2d}
--------------------

Frequencies, proportions, medians, IQR, means and SD described the study sample. The prevalence of opioid use, as well as crude overall mean OME taken and days of opioid use per subgroup were calculated. The adjusted change in mean OME and mean days of opioid use from pre-THA to post-THA were calculated using generalised linear models. Logistic regression models were used to identify risk factors associated with persistent chronic opioid use and new chronic opioid use after surgery. In both models, all candidate covariates were modelled in a bivariate model with the outcome of interest. If their association with the outcome had a p\<0.2, then these were included in the subsequent multivariable model. Collinearity between the variables in final models was evaluated, and tolerance values were \>0.1 in all cases. ORs and 95% CIs are provided. All tests were two-sided, and α=0.05 was considered statistically significant. SAS V.9.4 (SAS Institute, Cary, North Carolina, USA) was used for all analyses.

Sensitivity analysis {#s2e}
--------------------

High and long-term use of non-steroidal anti-inflammatory drugs are risk factors for gastric acid disease, a condition treated with proton-pump inhibitors;[@R29] [@R30] therefore, we tested this interaction in a sensitivity analysis---no interaction was found and data are not shown.

Patient involvement {#s2f}
-------------------

No patients were involved in the design of this study, in developing the outcome measures nor in the conduct of the study. There are no plans to disseminate the results to study participants.

Results {#s3}
=======

Our cohort of 9525 primary THAs was 51.3% (n=4891) women and had a median age of 80 years (5th--95th centile 76--84 years) at the time of surgery. [Table 1](#BMJOPEN2015010664TB1){ref-type="table"} describes patients\' characteristics, comorbidities and other analgesic medication use pre-THA and post-THA as per their pre-THA chronic opioid use status.

Presurgery, 6.2% (n=593) of patients were considered chronic opioid users, while 5.2% (n=492) were users postsurgery. Of the 492 chronic users post-THA, 61.4% (n=302) were persistent chronic users (chronic users pre-THA and post-THA) and 38.6% (n=190) became chronic users after surgery (ie, 38 were considered 'none' and 152 were considered 'some' users pre-THA). On average, a chronic opioid user before surgery had 55.5 (95% CI 51.4 to 59.7) OMEs mg/day and was dispensed opioids for 189.9 (95% CI 185.69 to 193.9) days. Postsurgery they had 57.5 (95% CI 52.1 to 62.8) OMEs mg/day and were dispensed opioids for 193.0 (95% CI 188.8 to 197.1) days. See [table 2](#BMJOPEN2015010664TB2){ref-type="table"} for prevalence of opioid use type, daily OMEs and average number of days for each group, as well as changes in the group pre-THA and post-THA.

###### 

Prevalence of opioid use, mean daily oral morphine equivalents use, and days of use pre-THA and post-THA by opioid user status, and change in daily use and days by pre-THA to post-THA status

                                                                             Opioid use post-THA      Opioid use pre-THA                                
  -------------------------------------------------------------------------- ------------------------ ------------------------ ------------------------ ---------------------------
  Prevalence, n (%)                                                                                                                                     
   Total                                                                     9525                     5138 (5339)              3794 (39.8)              593 (6.2)
   None                                                                      6626 (69.6)              4369 (85.0)              2146 (56.6)              111 (18.7)
   Some                                                                      2407 (25.3)              731 (14.2)               1496 (39.4)              180 (30.4)
   Chronic                                                                   492 (5.2)                38 (0.7)                 152 (4.0)                302 (50.9)
  Daily OME use for group and change in daily OME use,\* mg, mean (95% CI)                                                                              
   Total                                                                                              0.0 (0.0 to 0.0)         38.3 (37.6 to 39.0)      55.5 (51.4 to 59.7)
   None                                                                      0.0 (0.0 to 0.0)         0.0 (−0.1 to 0.1)        −37.7 (−38.4 to −37.0)   −55.3 (−59.4 to −51.2)
   Some                                                                      37.5 (36.6 to 38.4)      36.6 (35.7 to 37.5)      −1.1 (−2.1 to −0.1)      −18.7 (−22.9 to −14.5)
   Chronic                                                                   57.5 (52.1 to 62.8)      56.2 (51.2 to 61.2)      18.6 (13.6 to 23.6)      0.9 (−3.2 to 5.0)
  Days using opioids for group and change in days use,\* mean (95% CI)                                                                                  
   Total                                                                                              0.0 (0.0 to 0.0)         27.0 (26.1 to 27.9)      189.9 (185.9 to 193.9)
   None                                                                      0.0 (0.0 to 0.0)         −0.2 (−0.3 to −0.1)      −25.9 (−26.8 to −25.0)   −187.0 (−190.9 to −183.1)
   Some                                                                      24.4 (23.3 to 25.5)      22.7 (21.6 to 23.8)      −3.0 (−4.3 to −1.7)      −164.0 (−168.1 to −159.9)
   Chronic                                                                   193.0 (188.8 to 197.1)   189.0 (184.8 to 193.2)   163.3 (159.1 to 167.5)   2.6 (−2.3 to 7.5)

\*Adjusted for age, sex, surgical indication, bilateral status, RxRisk-V comorbidity burden, back pain, year of operation, and prior THA and post-THA other analgesic medication use.

OME, oral morphine equivalents; THA, total hip arthroplasty.

Risk factors for persistent chronic opioid use were younger age (OR=0.96, 95% CI 0.93 to 0.99/1-year increment), presence of back pain (OR=1.99, 95% CI 1.20 to 3.23), uncomplicated diabetes (OR=3.52, 95% CI 1.05 to 11.8) and use of hypnotics pre-THA (OR=2.52, 95% CI 1.48 to 4.30). The number of days on opioids prior to surgery was associated with odds of continuing to be a chronic opioid user after surgery after 94 days using opioids. Compared with opioid use for 94--157 days, patients who used opioids for 157--224 days had a 3.75 (95% CI 2.28 to 6.18) higher odds of being a persistent user, and those who used it for 225+ days had a 5.18 (95% CI 2.92 to 9.19) higher odds ([table 3](#BMJOPEN2015010664TB3){ref-type="table"}).

###### 

Risk factors of persistent chronic opioid use after THA in patients who were chronic user presurgery (N=302/593)

  Risk factor                                            Crude OR (95% CI)     p Value   Adjusted OR (95% CI)   p Value
  ------------------------------------------------------ --------------------- --------- ---------------------- -----------
  Demographics                                                                                                  
   Age (per 10-year increment)                           0.97 (0.95 to 0.98)   \<0.001   0.96 (0.93 to 0.99)    \<0.001\*
  Opioid-related comorbidities                                                                                  
   Back pain                                             1.69 (1.20 to 2.38)   0.003     1.99 (1.20 to 3.23)    0.008\*
   Depression                                            1.60 (1.12 to 2.28)   0.009     1.14 (0.67 to 1.96)    0.629
   Psychoses                                             1.97 (0.78 to 4.96)   0.149     1.47 (0.39 to 5.42)    0.563
  Medical comorbidities                                                                                         
   Diabetes with complications                           2.19 (1.12 to 3.87)   0.007     3.52 (1.05 to 11.8)    0.042\*
   IHD hypertension                                      0.80 (0.58 to 1.12)   0.199     0.66 (0.41 to 1.07)    0.090
   Diabetes uncomplicated                                2.17 (1.36 to 3.45)   0.001     1.89 (0.78 to 4.57)    0.160
   Liver disease (severe) or failure                     1.49 (0.89 to 2.50)   0.129     1.25 (0.59 to 2.66)    0.566
   Migraine                                              2.93 (0.59 to 14.6)   0.190     1.76 (0.18 to 17.3)    0.628
   Hypertension                                          1.28 (0.92 to 1.79)   0.147     0.98 (0.59 to 1.63)    0.934
   RA/collage vascular disorders                         2.46 (0.76 to 7.92)   0.133     1.01 (0.25 to 4.71)    0.925
  Analgesic use                                                                                                 
   Days using opioids prior to surgery                                         \<0.001                          \<0.001
    \<94                                                 --†                             --†                    
    94--156                                              Ref                             Ref                    
    157--224                                             3.75 (2.28 to 6.18)             3.63 (2.08 to 6.34)    
    225+                                                 4.85 (2.89 to 8.15)             5.18 (2.92 to 9.19)    
   Average daily use of opioids (per 10 OME increment)   1.11 (1.06 to 1.15)             1.06 (1.00 to 1.11)    0.065
   Pre-THA: hypnotics and sedatives                      1.72 (1.21 to 2.42)   0.002     2.52 (1.48 to 4.30)    \<0.001\*

\*Significant variables (p\<0.05) in final model.

†No cases of persistent chronic users in this group, could not model this level.

IHD, ischaemic heart disease; OME, oral morphine equivalents; RA, rheumatoid arthritis; Ref, reference; THA, total hip arthroplasty.

Risk factors for patients to develop chronic opioid use after THA were being a woman (OR=1.40, 95% CI 1.00 to 1.96), presence of back pain (OR=3.90, 95% CI 2.85 to 5.33), depression (OR=1.70, 95% CI 1.20 to 2.41), migraine (OR=5.30, 95% CI 1.12 to 25.01), liver disease (mild; OR=4.33, 95% CI 1.08 to 17.35), weight loss (OR=2.60, 95% CI 1.06 to 6.39), dementia (OR=2.19, 95% CI 1.06 to 6.39), gastric acid disease (OR=1.62, 95% CI 1.16 to 2.25), hyperlipidaemia (OR=1.38, 95% CI 1.00 to 1.91), and preoperative use of hypnotics (OR=1.56, 95% CI 1.13 to 2.16) and antineuropathic pain medication (OR=3.11, 95% CI 2.05 to 4.72; [table 4](#BMJOPEN2015010664TB4){ref-type="table"}).

###### 

Risk factors for developing new chronic opioid use after THA surgery (N=190/8932)

  Risk factor                                 Crude OR (95% CI)      p Value   Adjusted OR (95% CI)   p Value
  ------------------------------------------- ---------------------- --------- ---------------------- -----------
  Demographics                                                                                        
   Sex: women vs men                          1.47 (1.09 to 1.97)    0.011     1.40 (1.00 to 1.96)    0.049\*
  Opioid-related comorbidities                                                                        
   Back pain                                  5.52 (4.12 to 7.41)    \<0.001   3.90 (2.85 to 5.33)    \<0.001\*
   Depression                                 2.13 (1.56 to 2.93)    \<0.001   1.70 (1.20 to 2.41)    0.003\*
   Alcohol abuse                              3.08 (1.23 to 7.71)    0.016     2.16 (0.75 to 6.22)    0.152
   Psychoses                                  2.98 (1.55 to 5.74)    0.001     1.39 (0.65 to 2.96)    0.392
   Anxiety                                    1.66 (1.14 to 2.43)    0.009     1.00 (0.66 to 1.50)    0.990
  Medical comorbidities                                                                               
   Migraine                                   5.16 (1.19 to 22.38)   0.028     5.11 (1.08 to 24.18)   0.040\*
   Liver mild disease                         7.37 (2.16 to 25.10)   0.001     4.33 (1.08 to 17.35)   0.039\*
   Weight loss                                3.82 (1.64 to 8.89)    0.002     2.60 (1.06 to 6.39)    0.038\*
   Dementia                                   2.79 (1.40 to 5.56)    0.003     2.19 (1.04 to 4.61)    0.039\*
   Gastric acid disease                       2.49 (1.84 to 3.36)    \<0.001   1.62 (1.16 to 2.25)    0.004\*
   Hyperlipidaemia                            1.76 (1.32 to 2.34)    \<0.001   1.38 (1.00 to 1.91)    0.048\*
   Diabetes with complications                2.08 (1.34 to 3.25)    0.001     1.86 (0.97 to 3.57)    0.063
   Epilepsy                                   3.15 (1.97 to 5.02)    \<0.001   1.01 (0.58 to 1.77)    0.972
   Benign prostatic hypertrophy               1.64 (0.89 to 3.05)    0.116     1.61 (0.81 to 3.22)    0.176
   Peripheral vascular disease                2.44 (1.27 to 4.68)    0.008     1.57 (0.77 to 3.19)    0.215
   Osteoporosis/Paget\'s                      1.89 (1.32 to 2.71)    0.001     1.30 (0.88 to 1.93)    0.186
   Myocardial infarction                      2.46 (1.32 to 4.59)    0.005     1.46 (0.73 to 2.94)    0.284
   Diabetes uncomplicated                     1.40 (0.92 to 2.13)    0.114     0.76 (0.41 to 1.39)    0.374
   Antiplatelets agents                       1.38 (1.03 to 1.85)    0.032     0.85 (0.61 to 1.17)    0.317
   Chronic pulmonary disease                  2.10 (1.30 to 3.41)    0.003     1.31 (0.74 to 2.33)    0.349
   Reactive airway disease                    1.33 (0.96 to 1.85)    0.091     0.89 (0.60 to 1.30)    0.538
   Hypothyroidism                             1.63 (1.02 to 2.61)    0.042     1.22 (0.74 to 2.00)    0.442
   Angina                                     1.86 (1.28 to 2.68)    0.001     1.18 (0.77 to 1.79)    0.446
   RA/collage vascular disorders              2.63 (1.06 to 6.54)    0.038     1.38 (0.49 to 3.84)    0.542
   Inflammatory bowel syndrome                2.55 (0.92 to 7.06)    0.071     1.37 (0.45 to 4.17)    0.583
   Liver disease (severe) or failure          2.21 (1.24 to 3.93)    0.007     1.10 (0.59 to 2.04)    0.764
   Congestive heart failure                   1.85 (1.30 to 2.64)    0.001     1.07 (0.72 to 1.60)    0.728
   Parkinson\'s disease                       2.23 (0.97 to 5.12)    0.059     1.14 (0.43 to 3.01)    0.796
   Renal disease/failure                      1.91 (1.10 to 3.32)    0.022     1.06 (0.59 to 1.91)    0.849
   Other neurological disorder                2.29 (0.92 to 5.68)    0.074     1.14 (0.38 to 3.44)    0.811
  Other analgesic use                                                                                 
   Pre-THA: hypnotics and sedatives           2.31 (1.70 to 3.12)    \<0.001   1.56 (1.13 to 2.16)    0.007\*
   Pre-THA: antineuropathic pain              4.72 (3.31 to 6.72)    \<0.001   3.11 (2.05 to 4.72)    \<0.001\*
   Pre-THA: muscle relaxants                  4.22 (0.87 to 18.06)   0.053     1.95 (0.39 to 9.74)    0.416
   Pre-THA: corticosteroids                   1.78 (1.25 to 2.55)    0.002     1.17 (0.79 to 1.74)    0.430
   Bilateral procedure (more than 365 days)   0.60 (0.36 to 1.00)    0.049     0.70 (0.41 to 1.20)    0.194

\*Significant variables (p\<0.05) in final model.

RA, rheumatoid arthritis; THA, total hip arthroplasty.

Discussion {#s4}
==========

In this large cohort of patients who had undergone THAs, we determined that 6.2% of patients were chronic opioid users before surgery, and 5.2% were chronic opioid users after surgery. After THA, 61.4% of the chronic users of opioid had been chronic users before surgery, and 38.6% of them were new chronic users postsurgery. After evaluating patient characteristics, 56 patient comorbidities and other analgesic medication, we identified several risk factors associated with chronic opioid use.

Both sex and age were associated with chronic opioid use. Being female was associated with a 40% higher risk of developing chronic opioid use after surgery. Identifying women at a higher risk of chronic use in a THA population is consistent with studies that evaluated different aspects of the sex and pain relationship. Specifically, women are at a higher risk of acute pain after THA surgery,[@R31] as well as persistent and chronic postoperative pain;[@R32] therefore, women had higher general utilisation of opioids in the long term.[@R6] [@R7] We also found that chronic opioid users were younger. While this was not a risk factor for development of new chronic opioid use post-THA, it was a risk factor for persistent chronic use or not reducing use after surgery. There is some evidence that younger patients are at a higher risk of persistent opioid use in the general surgical population.[@R33] It has also been suggested that younger patients utilise higher perioperative opioid amounts.[@R34] This higher utilisation is reported even without consistent evidence that younger patients experience greater pain from the procedure; for example, Liu *et al*[@R31] reported higher scores for moderate-to-severe pain in younger patients, but Petre *et al*[@R34] did not.

There are several opioid-related comorbidities associated with higher risk of chronic opioid use in our cohort. Back pain was the condition most consistently associated with chronic opioid use. Patients with back pain, diagnosed prior to surgery, were four times more likely to develop chronic opioid use if they did not already have it, and two times more likely to continue their chronic use after surgery. In the general population, back pain is one of the strongest predictors for opioid abuse,[@R35] and its association with the pain and utilisation of opioids in a THA population[@R7] is expectedly strong.[@R20] Another condition commonly associated with high opioid utilisation and abuse, which was also found in our study, was depression.[@R36] Depression was risk factor for new chronic opioid use. This has been reported in at least two other THA cohorts, one which assessed depression using patient medication assessments and one via a patient-reported questionnaire.[@R31] [@R37]

One of the strongest general medical comorbidities risk factor for new opioid chronic use was pre-THA migraine, a condition associated with chronic pain and one where opioids are recommended for pain treatment.[@R38] Liver disease was also strongly associated with new chronic opioid use, confirming previously reported associations in non-THA cohorts.[@R39] Dementia, a moderate risk factor for new chronic use, was reportedly associated with chronic opioid use in general cohorts of patients, but to our knowledge, this is the first time it is reported in a THA cohort.[@R40] The dispensing of proton-pump inhibitors was used to identify patients suffering from gastric acid disorder, a condition present in 44% of our cohort. We found this condition to be weakly associated with new chronic use development, which to our knowledge has also not been previously reported. We did not assess the duration of proton-pump inhibitors use. While the majority of people who took these medications did not become chronic opioid users, long-term use of proton-pump inhibitors has been shown to increase the risk of bone fracture[@R41] and surgical site infections,[@R42] events that if present or developing after surgery could lead to the development of chronic opioid use after surgery. Weight loss, a moderate risk factor for new chronic use, and hyperlipidaemia, a borderline risk factor for chronic opioid use, were identified, but to our knowledge such associations have not been previously evaluated and we cannot, therefore, make comparisons. Finally, some established risk factors for chronic opioid use, including psychiatric comorbidities, alcohol and substance abuse, were not observed in our study. It is likely that these comorbidities were either well managed in these patients or the higher risk of opioid abuse in them was recognised and properly managed by their providers.

Diabetes was a moderate risk factor for persistent opioid use in this study. This has also been reported in other major elective surgical procedures[@R33] and corroborates a recent report of it being associated with persistent pain post-THA.[@R5] Rajamäki *et al*[@R5] suggested that either the constant chronic inflammation state that patients with diabetes are in or diabetic-related complications, such as neuropathy, could be associated with the mechanism to explain opioid use in patients with THA.

Prior opioid and adjuvant analgesics usage were also associated with risk of persistent or new chronic opioid use. The greater the number of days someone was dispensed opioids prior to surgery was associated with a higher likelihood of continuing to be a chronic user, which is consistent with studies reporting that the greater exposure to opioids, the greater the risk of abuse.[@R43] Use of other medications, such tricyclic antidepressants and anticonvulsants, recommended for neuropathic pain, was also associated with a higher risk of persistent and new chronic use; this again confirms findings from general major elective surgical populations.[@R33]

Our study could not determine whether opioid use was associated with pain in the index joint. While we believe that opioid use is an efficient proxy for pain assessment measurement in joint replacement patients, as it identifies someone who has been prescribed a medication that is only recommended for refractory pain management,[@R1] we understand that measuring and evaluating pain is difficult and more complex than only using opioid prescriptions.[@R44] We also could not identify the reasons for the other analgesic medication patients were taking during the study timeline. It is possible they were prescribed these medications for reasons other than the joint pain. Additionally, our observational study used prescriptions to measure opioid use in this cohort of patients; therefore, we do not know whether patients were compliant to medication instructions.

Our study limitations include the conservative definition of chronic opioid user as someone who was prescribed opioids for 90 consecutive days or 120 non-consecutive days, which could miss the identification of opioid abuse (ie, overdoses or poisoning earlier on) in this patient population. We tried to include as many comorbidities, including those like migraine that is considered to be a chronic pain condition, in our analysis, but it is still possible that other chronic pain conditions, such as fibromyalgia, can be present and not accounted for in our analysis, both as a possible risk factor and as a confounder of the other relationships studied. Other confounding variables that we were unable to assess, such as body mass index, psychological well-being, function status, prescribers\' preferences, as well as information regarding the index surgery, such as intraoperative complications, anaesthesia, length of stay and discharge destination, could affect the relationship between the risk factors we identified for persistent or new chronic use of opioid. Also, it is possible that due to the relatively low proportion of patients with some of the risk factors assessed, we may have been underpowered to detect associations between these factors and the likelihood of chronic or persistent opioid use. Finally, our study was comprised of an older cohort of Australian patients, making our results possibly less generalisable to a younger joint-replacement population.

The strengths of our study include our large patient cohort, which allowed for robust estimates on various risk factors. In an attempt to provide the most comprehensive assessment of patient comorbidities, we used three comorbidity measures to identify conditions using both inpatient hospitalisations and medication history. Our use of pharmacy data to determine opioid use, which provided us with more detailed information on the medication used by the study cohort, was less subject to recall bias than other studies that relied on patient or surgeon-reported measurements. Finally, the DVA administrative data used in this study covers all services provided to the Australian veteran population, assuring that we had complete data on all the procedures, hospitalisations and medications provided to these patients. This guaranteed to our study a low risk of missing data and attrition in the cohort.

Conclusion {#s5}
==========

Of the 492 (5% of the total cohort) chronic opioid users after THA, 61% were persistent chronic users and 39% became chronic users after surgery. Back pain, diabetes and preoperative use of hypnotics were strong risk factors for the persistent and new development of chronic opioid use. Additional risk factors for persistent use included younger age and longer use of opioids prior to surgery, while for new chronic use these included being a woman, depression, migraine, gastric acid disease and antineuropathic pain medications. These indicators of chronic opioid use can be used by clinicians for risk stratification prior to THA surgery, and will help to target patient groups for suitable pain management interventions presurgery and postsurgery.
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